Effect of dilution on high-density lipoprotein associated paraoxonase-1 activity

Clinical Biochemistry

Volumn 44, Issue 14-15, 2011, Pages 1270-1271

  Mackness, Mike ^a   Mackness, Bharti ^a  

^a Pontech Art   (Spain)

Author keywords

Activity assays; HDL; Paraoxonase 1

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; PARAOXON; PHENYLACETIC ACID;

ARTICLE; DILUTION; ENZYME ACTIVITY; PH; PRIORITY JOURNAL; SPECTROPHOTOMETRY; ULTRACENTRIFUGATION;

ANIMALS; ARYLDIALKYLPHOSPHATASE; CHEMISTRY TECHNIQUES, ANALYTICAL; CHOLESTEROL, HDL; HUMANS; LIPOPROTEINS, HDL; PARAOXON; SHEEP;

EID: 80052949159     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.08.002     Document Type: Article

References (6)

1. Draganov D.I., La Du B.N. Pharmacogenetics of paraoxonase: a brief review. Naunyn Schmiedebergs Arch Pharmacol 2004, 369:78-88.
2. Mackness B., Quarck R., Verreth W., Mackness M., Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 2006, 26:1545-1550.
3. Mackness B., Hine D., Liu Y., Mastorikou M., Mackness M. Paraoxonase 1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. BBRC 2004, 318:680-683.
4. Mackness M.I., Abbott C.A., Arrol S., Durrington P.N. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993, 294:829-835.
5. Harel M., Aharoni A., Gaidukov L., et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 2004, 11:412-419.
6. Kontush A., Chapman M.J. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol 2010, 21:312-318.